Article

Erin Crown, PA-C: Using Telemedicine to Help Schizophrenia Patients

Author(s):

Because symptoms can manifest differently in each patient, some individuals with schizophrenia have handled social isolation better than others.

With therapy sessions going virtual due to the coronavirus disease 2019 (COVID-19), schizophrenia patients have handled the changes very differently.

In an interview with HCPLive®, Erin C. Crown, PA-C, a physician’s assistant for Oasis Lifecare, explained how some of her patients have handled social isolation differently than others.

Because schizophrenia can manifest in different ways and not all patients have the same subset of symptoms, Crown said some patients are more adaptable to social isolation because they were already isolating themselves.

Patients who suffer from delusions or hallucinations will likely take to social isolations better because they tend to socially isolate anyway.

For others, there is more of an adjustment to the current circumstances, including patients who suffer from increased paranoia and anxiety due to concern over the pandemic and it’s causes and potential damage.

Even some of the more stable patients can have a tough time with anxiety and sleep with concern over their health and the health of their loved ones.

Along with dealing with the stress of the situation, most schizophrenia patients, at least briefly, were asked to transition from in-person therapy sessions to virtual meetings. Again, some patients have been able to transition seamlessly to virtual appointments, while others have struggled and either stopped therapy or mandated in-person care.

Related Videos
Parent Stress Reduces Over Time When Weaning Child Off Tube Feeding with Hide Okuno, MS
Impact of Long Hospital Stays on Pediatric Gastroparesis Management with Christian Sadaka, MD
Christian Sadaka, MD: Significant Increase in Pediatric Gastroparesis Hospital Admissions After COVID-19
Akif Shameem, MD: Generalized Anxiety Disorder Linked to Longer Hospitals in Children with IBD
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Jonathan Meyer, MD: Cognitive Gains, Dopamine-Free Schizophrenia Treatment with Xanomeline Trospium Chloride
Chelsie Monroe: Challenges Clinicians Should Consider When Prescribing Muscarinic Modulators for Schizophrenia
Thumbnail for schizophrenia special report around approval of Cobenfy.
© 2024 MJH Life Sciences

All rights reserved.